Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
per week
for first 24 weeks

Enjoy unlimited digital access
Cancel Anytime
Enjoy Unlimited Digital Access
Canada’s most-awarded
newsroom for a reason
Stay informed for a
lot less, cancel anytime
“Exemplary reporting on
COVID-19” – Herman L
per week
for 24 weeks
Get full access to
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(}function setPanelState(o){dom.root.classList[o?"add":"remove"](,dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Thalidomide victim Mercedes Benegbi pauses during a news conference on Parliament Hill supporting NDP motion calling for compensation for Thalidomide survivors.

Dave Chan/The Globe and Mail

The Conservative government has committed to providing support for victims of the drug thalidomide, a move that will pave the way for new compensation in one of the worst health scandals in Canada's history.

The announcement that the Tories will vote in favour of a parliamentary motion calling for "full support" came after Prime Minister Stephen Harper served notice in the Commons on Wednesday he wants to resolve the matter. The Globe and Mail recently detailed the struggles of people living with the debilitating effects of a federally approved drug their mothers were given in the 1960s, a memory invoked by the Prime Minister himself.

"This is a terrible series of events that those of us who were raised in the 1960s remember very well," Mr. Harper said. He acknowledged Ottawa previously compensated the victims, "but we understand that there are ongoing needs," he said.

Story continues below advertisement

"We look forward to moving forward on this matter," Mr. Harper told MPs when asked about the request from the Thalidomide Victims Association of Canada, which is seeking long-term aid for the 95 survivors.

The Conservatives have not made a specific commitment and have given no sign they are prepared to offer the long-term, annual support victims say is required to live with dignity as they age.

But Health Minister Rona Ambrose's office said it is committed to backing the motion on Thursday in the House of Commons. NDP health critic Libby Davies brought the motion, which says the government "should provide support to survivors as requested by the Thalidomide Survivors Taskforce."

"We intend on supporting, and are currently working, to find a way to best support this motion," said Michael Bolkenius, press secretary to Ms. Ambrose.

Canadian victims of thalidomide were born in the early 1960s with birth defects such as flipper-like hands, stunted legs, deafness and internal organ damage.

The support of the Conservatives with their Commons majority means the motion will pass. The Liberals also back it.

Victims say they are encouraged by the government's support, but caution the process to work out a financial aid package has just begun.

Story continues below advertisement

Until The Globe and Mail exposed the plight of the country's survivors, Ms. Ambrose did not return the group's calls.

"This is only a start," said Mercédes Benegbi, head of the Thalidomide Victims Association of Canada. "But it's a positive start."

The group had wanted a public sign of government support before agreeing to sit down with Ms. Ambrose. That sign came with the commitment to support the NDP motion. The group says it is now looking forward to working with Ms. Ambrose.

"This is very encouraging. It shows goodwill by the government," Ms. Benegbi said. "We're confident we're going to find a solution to the crisis facing Canada's thalidomide survivors."

Victims across the country are coping with growing health problems, and some cannot afford basic care. Many find it increasingly difficult to carry out everyday tasks like housekeeping and meal preparation, because their disabilities have caused wear and tear on their bodies.

Ms. Davies said she expects a slight modification to the motion that will talk about the thalidomide group working co-operatively with the government on the matter. But it will not change the substance of the motion.

Story continues below advertisement

"It's going to be one of those rare moments in Parliament where we show we can come together and do the right thing," Ms. Davies said.

Ms. Ambrose signalled on Tuesday that she was prepared to meet with the group.

The mothers of thalidomide victims, while pregnant, were prescribed the drug for symptoms such as insomnia and morning sickness. In late 1960, Ottawa approved the medicine for use and it was on the market between 1961 and 1962. The United States never approved thalidomide.

In 1991, the former Progressive Conservative government gave Canadian victims a one-time compensation payout without any admission of liability. It came to $52,000 to $82,000 a person, depending on their degree of disability. The one-time payment is far less than the continuing support offered in countries such as Germany and the United Kingdom.

Canada was one of the last countries to stop thalidomide sales and has never apologized to those affected by its use.

The Thalidomide Victims Association of Canada wants $100,000 a year on average for survivors, plus a lump-sum payment to ensure those afflicted "can survive and age with dignity."

Story continues below advertisement

Liberal MP Carolyn Bennett, a physician, said, "Their quality of life is really suffering. They're getting older and need help with their activities of daily living. It just seems like the right thing to do and to acknowledge the government of Canada did approve this drug."

The one-time compensation payments made to victims in the 1990s – when they were in their late 20s – were used to cover pressing needs such as electric wheelchairs, and nothing is left. The victims, now in their early 50s, say they require regular pensions to enable them to face their growing health needs. Many are aging prematurely due to their disabilities.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the authors of this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to If you want to write a letter to the editor, please forward to

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies